Replies to post #69051 on Ariad Pharmaceuticals Inc fka ARIA

[vidpok45]

Good post. In the absence of news, speculative posts based on nothing but projections of one's personal bias rule the day. I would guess that the lack of transparency by management is because they are in negotiations for a sale and don't want to jeopardize the process by releasing information. That's the only reason I can imagine for the complete silence for so long. No one here has any clue as to what actually is going on, and to post messages as factual statements which are not is misleading and reflects poorly on the messenger.

[biotech_researcher]

flexinvestor, the following is FACT: How can you say the value of the compounds is the same as before the crash when before the crash, Iclusig didn't have this warning label: Arterial and venous thrombosis and occlusions have occurred in at least 27% of Iclusig treated patients

I can assure everyone on this board that this is NOT a Best in Class drug:

Vascular Occlusion: Arterial and venous thrombosis and occlusions have occurred in at least 27% of Iclusig treated patients, including fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients less than 50 years old, experienced these events. Monitor for evidence of thromboembolism and vascular occlusion. Interrupt or stop Iclusig immediately for vascular occlusion. A benefit risk consideration should guide a decision to restart Iclusig therapy.
Heart Failure, including fatalities, occurred in 8% of Iclusig-treated patients. Monitor cardiac function. Interrupt or stop Iclusig for new or worsening heart failure.
Hepatotoxicity, liver failure and death have occurred in Iclusig-treated patients. Monitor hepatic function. Interrupt Iclusig if hepatotoxicity is suspected.

[STOCKSEEK]

Completely agree Flex.